1 study on Cagrisema curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 3 published Cagrisema COA source records from third-party laboratories, covering 1 publicly attributable vendor identity. A positive-purity mean is not available. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 0 records report measured amount more than 10% below the label. The latest recorded test date is 2025-11-10. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $9.50 | $9.50–$9.50 | $1.90 | 1 source · 1 offer |
| 10 mg | $17.00 | $17.00–$17.00 | $1.70 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2025-11-10. Aggregate calculated: 2026-10-18T06:20:47.661831+00:00. Calculation time is not a laboratory observation date.
Within that total, 2 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Optimizing CagriSema dosing could expand treatment options for obesity by identifying regimens that balance efficacy with improved tolerability, potentially leading to broader patient adoption and adherence. Finding e…
Free, no account — handy when you're working with Cagrisema.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account